Baseline characteristics of the CASTING Study population: a Phase IIIB Trial evaluating Ocrelizumab in patients with relapsing-remitting Multiple Sclerosis and suboptimal response to disease-modifying therapies

被引：0
|
作者：
Vermersch, P. [1 ]
Comi, G. [2 ]
Siva, A. [3 ]
Oreja-Guevara, C. [4 ]
Wiendl, H. [5 ]
Van Wijmeersch, B. [6 ]
Eralinna, J. -P. [7 ]
Nicholas, R. [8 ]
Buffels, R. [9 ]
Bernasconi, C. [9 ]
Kuhelj, R. [9 ]
机构：
[1] Univ Lille, Lille, France
[2] Univ Vita Salute San Raffaele, Milan, Italy
[3] Istanbul Univ, Istanbul, Turkey
[4] Univ Hosp San Carlos, Madrid, Spain
[5] Univ Munster, Munster, Germany
[6] Univ Hasselt, Rehabil & MS Ctr Overpelt, BIOMED, Hasselt, Belgium
[7] Univ Turku, Turku, Finland
[8] Imperial Coll London, London, England
[9] F Hoffmann La Roche Ltd, Basel, Switzerland
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2018年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPO2077
引用
收藏
页码：190 / 190
页数：1
相关论文
共 50 条
  • [31] Evaluation of Selected Oxidant/Antioxidant Parameters in Patients with Relapsing-Remitting Multiple Sclerosis Undergoing Disease-Modifying Therapies
    Bizon, Anna
    Chojdak-Lukasiewicz, Justyna
    Koltuniuk, Aleksandra
    Budrewicz, Slawomir
    Pokryszko-Dragan, Anna
    Piwowar, Agnieszka
    ANTIOXIDANTS, 2022, 11 (12)
  • [32] Disease-modifying effect of circuit class therapy in patients with relapsing-remitting multiple sclerosis
    Kolcava, J.
    Vlckova, E.
    Kocica, J.
    Sladeckova, M.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 395 - 396
  • [33] Effectiveness and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis who had a suboptimal response with prior disease-modifying therapy: 2-year findings from CHORDS
    Weinstock-Guttman, B.
    Bermel, R.
    Csoboth, C.
    Cutter, G.
    Freedman, M.
    Leist, T. P.
    Ma, X.
    Musch, B.
    Reder, A.
    Stankiewicz, J.
    Wolinsky, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 43 - 43
  • [34] Olfactory dysfunction in patients with relapsing-remitting multiple sclerosis treated with disease modifying therapies
    Wnuk, M.
    Drabik, L.
    Marona, M.
    Szaleniec, J.
    Bryll, A.
    Karcz, P.
    Kolasinska, J.
    Kolasinska, M.
    Ziekiewicz, M.
    Skladzien, J.
    Popiela, T.
    Slowik, A.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 542 - 543
  • [35] Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis
    Roos, Izanne
    Malpas, Charles
    Leray, Emmanuelle
    Casey, Romain
    Horakova, Dana
    Havrdova, Eva Kubala
    Debouverie, Marc
    Patti, Francesco
    De Seze, Jerome
    Izquierdo, Guillermo
    Eichau, Sara
    Edan, Gilles
    Prat, Alexandre
    Girard, Marc
    Ozakbas, Serkan
    Grammond, Pierre
    Zephir, Helene
    Ciron, Jonathan
    Maillart, Elisabeth
    Moreau, Thibault
    Amato, Maria Pia
    Labauge, Pierre
    Alroughani, Raed
    Buzzard, Katherine
    Skibina, Olga
    Terzi, Murat
    Laplaud, David Axel
    Berger, Eric
    Grand'Maison, Francois
    Lebrun-Frenay, Christine
    Cartechini, Elisabetta
    Boz, Cavit
    Lechner-Scott, Jeannette
    Clavelou, Pierre
    Stankoff, Bruno
    Prevost, Julie
    Kappos, Ludwig
    Pelletier, Jean
    Shaygannejad, Vahid
    Yamout, Bassem, I
    Khoury, Samia J.
    Gerlach, Oliver
    Spitaleri, Daniele L. A.
    Van Pesch, Vincent
    Gout, Olivier
    Turkoglu, Recai
    Heinzlef, Olivier
    Thouvenot, Eric
    McCombe, Pamela Ann
    Soysal, Aysun
    NEUROLOGY, 2022, 99 (17) : E1926 - E1944
  • [36] Disease modifying therapies discontinuation in relapsing-remitting Multiple Sclerosis: a monocentric cohort study
    Pasca, M.
    Forci, B.
    Mechi, C.
    Mariottini, A.
    Barilaro, A.
    Massacesi, L.
    Repice, A. M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 464 - 465
  • [37] The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis
    Devonshire, V.
    Lapierre, Y.
    Macdonell, R.
    Ramo-Tello, C.
    Patti, F.
    Fontoura, P.
    Suchet, L.
    Hyde, R.
    Balla, I.
    Frohman, E. M.
    Kieseier, B. C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2011, 18 (01) : 69 - 77
  • [38] Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis
    Zimmermann, Marita
    Brouwer, Elizabeth
    Tice, Jeffrey A.
    Seidner, Matt
    Loos, Anne M.
    Liu, Shanshan
    Chapman, Richard H.
    Kumar, Varun
    Carlson, Josh J.
    CNS DRUGS, 2018, 32 (12) : 1145 - 1157
  • [39] Disease-Modifying Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis: A Comparison of Their Efficacy for Reducing Relapse Rate
    Lingohr-Smith, M.
    Deitelzweig, C.
    Lin, G.
    Lin, J.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (1_SUPPL) : 34 - 35
  • [40] ESTIMATING THE FISCAL CONSEQUENCES OF INVESTMENTS IN DISEASE-MODIFYING THERAPIES FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY
    Mennini, F. S.
    Kotsopoulos, N.
    Connolly, M.
    Gianinazzi, M.
    Pellirone, M.
    Marcellusi, A.
    VALUE IN HEALTH, 2020, 23 : S627 - S628
12345